AI-based R&D
JW Pharmaceutical will increase its R&D competitiveness by utilizing an artificial intelligence solution.
The pharmaceutical firm said on May 2 that it signed a memorandum of understanding (MOU) with Syntekabio on joint research using an artificial intelligence (AI) platform based on genome big data .
According to the agreement, JW Pharmaceutical will increase the efficiency of research and development by discovering biomarkers of new drug candidates using drug reactivity prediction technology of the Personal Genome Map Platform (PMAP) of Syntekabio.
In addition, the company will apply Syntekabio's platform technology to the field of regenerative medicine for the treatment of neurological diseases, and research on expanding indications for drugs being developed and sold.
Along with this, we intend to broaden the scope of cooperation to the field of precision medicine such as nutritional supply in the body, comprehensive nutrition infusion system related to immunization promotion, and development of new concept diagnosis reagent.
Syntekabio is a research institute-type company of the Korea Electronics and Telecommunication Research Institute (ETRI). The company discovered genetic biomarkers and developed an anticancer drug response prediction platformby combininggenomic big data and insilico technology and is currently studying patient stratification. The company has drawn up a plan to build the largest cloud-based genome big data platform in Korea via collaboration with Naver Cloud and expects the plan to give momentum to AI-based new drug development.
- Stem Cell-based Atopic Dermatitis Drug Expected to Become Available in 2019
- Korea’s Pharmaceutical Exports Reach 3.6 Trillion Won
- R&D Spending to Sales of Top 10 Pharmaceutical Firms Posted Double Digits
- 11 Companies to be Included into KOSPI 200 Index
- Domestic Pharmaceutical Companies Entering Saudi Arabia, then Middle East
- JW Holdings Accelerate Foray into 'Pharmerging' Markets
- Korean Pharma Firms Muscle into the US
- Orphan Drugs Become New Niche Market for Korean Pharmaceutical Firms
- JW Pharmaceutical Signs Joint Research Agreement with Singapore’s R&D Institute